Revolution Medicines (RVMD) Gains from Investment Securities (2023 - 2026)

Revolution Medicines' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $15.8 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 747.31% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $33.6 million (up 1275.53% YoY), while the FY2025 annual figure was $15.4 million, up 455.26% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $15.8 million, up from $12.6 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $15.8 million in Q1 2026, with the low at -$3.9 million in Q1 2024.
• The 4-year median for Gains from Investment Securities is $406000.0 (2024), against an average of $2.7 million.
• Peak annual rise in Gains from Investment Securities reached 5639.55% in 2025, while the deepest fall reached 53.35% in 2025.
• Revolution Medicines' Gains from Investment Securities stood at $115000.0 in 2023, then surged by 91.3% to $220000.0 in 2024, then surged by 5639.55% to $12.6 million in 2025, then rose by 25.03% to $15.8 million in 2026.
• Business Quant data shows RVMD's Gains from Investment Securities at $15.8 million in Q1 2026, $12.6 million in Q4 2025, and $592000.0 in Q3 2025.